Tenzing Acquisition Corporation (TZAC) Shareholders Approve Reviva Deal

Tenzing Acquisition Corporation (NASDAQ:TZAC) announced that its shareholders have approved its $84.8 million combination with neuromedicine drug developer Reviva Pharmaceuticals. Vote redemption information was not provided in today’s 8-K, but all proposals passed by wide margins.  A press release announcing a closing date should be forthcoming, but the symbols are anticipated to be RVPH and
Read More